William Blair Initiates Coverage on BridgeBio Pharma (NASDAQ:BBIO)

William Blair began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO) in a note issued to investors on Tuesday, Marketbeat reports. The firm set an “outperform” rating on the stock.

A number of other research analysts have also recently commented on BBIO. Truist Financial upped their target price on shares of BridgeBio Pharma from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Oppenheimer reduced their price target on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th. Barclays initiated coverage on shares of BridgeBio Pharma in a report on Wednesday, January 28th. They issued an “overweight” rating on the stock. Morgan Stanley increased their price objective on shares of BridgeBio Pharma from $96.00 to $98.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, TD Cowen reiterated a “buy” rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Twenty-three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.35.

BridgeBio Pharma Stock Down 3.9%

BBIO stock opened at $71.39 on Tuesday. The business has a fifty day moving average of $73.32 and a two-hundred day moving average of $65.78. The stock has a market cap of $13.84 billion, a price-to-earnings ratio of -18.89 and a beta of 1.13. BridgeBio Pharma has a 52-week low of $28.33 and a 52-week high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The business had revenue of $154.18 million during the quarter, compared to the consensus estimate of $150.71 million. The firm’s revenue for the quarter was up 2521.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.40) EPS. As a group, sell-side analysts anticipate that BridgeBio Pharma will post -3.67 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Thomas Trimarchi sold 13,600 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total value of $1,016,192.00. Following the completion of the transaction, the chief financial officer owned 336,585 shares in the company, valued at approximately $25,149,631.20. The trade was a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Neil Kumar sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $71.94, for a total transaction of $2,877,600.00. Following the sale, the chief executive officer directly owned 695,686 shares in the company, valued at approximately $50,047,650.84. The trade was a 5.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 227,095 shares of company stock valued at $16,099,240. 18.20% of the stock is owned by company insiders.

Institutional Trading of BridgeBio Pharma

A number of large investors have recently modified their holdings of the stock. Strs Ohio raised its stake in shares of BridgeBio Pharma by 1.1% in the third quarter. Strs Ohio now owns 18,600 shares of the company’s stock valued at $966,000 after acquiring an additional 200 shares in the last quarter. GAMMA Investing LLC grew its stake in BridgeBio Pharma by 28.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock worth $53,000 after purchasing an additional 227 shares in the last quarter. Steward Partners Investment Advisory LLC increased its holdings in BridgeBio Pharma by 22.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock worth $54,000 after purchasing an additional 228 shares during the period. Commonwealth Equity Services LLC increased its holdings in BridgeBio Pharma by 4.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock worth $396,000 after purchasing an additional 244 shares during the period. Finally, Farther Finance Advisors LLC raised its position in BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after purchasing an additional 245 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Phase‑3 FORTIFY interim analysis for oral BBP‑418 showed early, sustained separation from placebo on ambulation endpoints (100MTT, 10MWT), favorable safety signals, and BridgeBio’s plan to submit an NDA in H1 2026 (U.S. launch targeted late‑2026/early‑2027) — a potential first approved therapy for LGMD2I/R9 if cleared. BBP-418 Phase 3 FORTIFY Interim Analysis
• Positive Sentiment: Positive conference/academic exposure — additional FORTIFY data were presented at MDA and BridgeBio participated in investor conferences (Barclays), increasing visibility among clinicians and investors. Barclays Conference Transcript
• Positive Sentiment: New/expanded analyst coverage and price‑target upgrades: William Blair initiated coverage at “Outperform” and several firms (including JPMorgan and others recently) have raised targets — supporting buy‑side momentum and higher headline valuations. William Blair Initiates Coverage
• Neutral Sentiment: HC Wainwright reiterated a Buy and $100 target but adjusted near‑term EPS forecasts (mix of upward and downward tweaks across 2026–2027), reflecting both optimism on commercial upside and uncertainty in near‑term modeling.
• Neutral Sentiment: Media coverage and short‑term trading headlines (price‑target/news driven pops and mentions on watch lists) are amplifying volume and volatility; reported short‑interest data in feeds appear inconsistent/zeroed and are not a reliable signal today.
• Negative Sentiment: Large insider selling activity noted in aggregate disclosures (multiple executives sold shares in recent months), which can weigh on investor sentiment even as clinical news is positive. Quiver Quant — Insider & Conference Summary
• Negative Sentiment: Regulatory and commercialization risk remains — interim data are promising but full NDA review, label, timing, and payer access are uncertain; investors should expect binary outcomes tied to FDA review and launch execution.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.